Pisa, January 12, 2026- The Board of Directors of PharmaNutra S.p.A.(the "Company" or the "Group" -MTA; Ticker PHN), a company specializing in mineral-based nutritional supplements and medical devices for muscles and joints, today approved the Group's preliminary sales figures for financial year 2025 (unaudited).
Preliminary results show double-digit revenue growth in 2025, confirming the success of the Group's internationalization strategy and the global recognition of its product lines.
"Achieving robust double-digit growth on increasingly significant revenues is an excellent result, which continues to support all the business lines we are expanding and which have already begun to make a relevant contribution to total revenues this year. It should be emphasised that we are talking about development based once again on organic growth, a factor that reinforces the quality of the company's choices and confirms the correctness of the direction taken in terms of growth drivers. These are factors - another aspect to highlight - that have yet to express their full potential, but are already showing the first tangible positive signs over the company's growth."
2025 SALES REVENUESConsolidated 2025 net revenues amounted to €131.7 million with an increase of €16.2 million (+14.0%) compared to 2024.
Revenues | by area of busines €/1000 | s 2025 | 2024 | Δ | Δ% | Incid 2025 | ence 2024 |
Italy | 82.514 | 75.593 | 6.922 | 9,2% | 62,6% | 65% | |
Rest of world | 49.194 | 39.905 | 9.289 | 23,3% | 37,4% | 35% | |
Total | 131.709 | 115.498 | 16.211 | 14,0% | 100% | 100% |
Revenues include €5.9 million (+117.5% compared to 2024) from new Business Units, confirming significant growth potential, particularly in the United States and Chinese markets.
Revenues of New Businesses €/1000 | 2025 | 2024 | Δ | Δ% | Incidence 2025 2024 | |
China | 3.257 | 1.871 | 1.386 | 74,1% | 54,9% | 68,6% |
Nutrition | 1.206 | 591 | 614 | 103,9% | 20,3% | 21,7% |
Pharmanutra USA | 1.327 | 173 | 1.153 | 664,8% | 22,4% | 6,4% |
Pharmanutra España | 139 | 90 | 49 | 54,1% | 2,3% | 3,3% |
Total | 5.928 | 2.725 | 3.203 | 117,5% | 100% | 100% |
Revenues from the Italian market, amounting approximately to €82.5 million (€75.6 million in 2024), increased by 9%, representing about 63% of total revenues (65% in 2024). Growth was driven by higher sales of finished products (+8%), medical instruments (+17%), and raw materials (+52%).
The Italian market remains challenging due to ongoing dynamics in the wholesale channel. For this reason, at the beginning of 2026, the Group implemented a major change in its domestic commercial organisation, aiming for a closer relationship with retail pharmacies and a stronger focus on medical-scientific content, a strategic asset for the Group.
SALES REVENUES - INTERNATIONALInternational sales revenues reached €49.2 million (compared to €39.9 million in 2024), an increase of
€9.3 million (+23%). As a result of the above, the impact of international revenues on total sales rose from about 35% in 2024 to approximately 37% in 2025.
International revenue growth was widespread across all regions where the Group operates, confirming the global success of its products, developed by using Sucrosomial® Technology, an innovative delivery system that protects micronutrient molecules, enhancing absorption and improving tolerability.
Revenues by geographic area €/1000 2025 | 2024 | Δ | Δ% | Incid 2025 | ence 2024 | |
Italy | 82.514 | 75.593 | 6.922 | 9,2% | 62,6% | 65,4% |
Total Italy | 82.514 | 75.593 | 6.922 | 9,2% | 62,6% | 65,4% |
Europe | 23.685 | 20.951 | 2.735 | 13,1% | 18,0% | 18,1% |
Middle East | 14.001 | 9.943 | 4.058 | 40,8% | 10,6% | 8,6% |
Far East | 4.775 | 2.911 | 1.864 | 64,0% | 3,6% | 2,5% |
North America | 2.336 | 847 | 1.489 | 175,7% | 1,8% | 0,7% |
South America | 1.672 | 2.554 | -882 | -34,5% | 1,3% | 2,2% |
Other | 2.724 | 2.699 | 25 | 0,9% | 2,1% | 2,3% |
Total Foreign Markets | 49.194 | 39.905 | 9.289 | 23,3% | 37,4% | 34,6% |
Total | 131.709 | 115.498 | 16.211 | 14,0% | 100% | 100% |
Breakdown by product line (Trademark), reported in the below chart, confirms the exceptional performance of Sidevit® B12, which achieved €2.6 million in revenues within just 12 months of launch, making it the most successful product introduction in Group's history.
Growth in other product lines was mainly driven by increased international sales of Sideral®, Apportal®, and Ultramag®.
Revenues by Product Line €/1000 | 2025 | 2024 | Δ | Δ% | Incid 2025 | ence 2024 |
Sideral | 91.814 | 81.069 | 10.745 | 13,3% | 69,7% | 70,2% |
Cetilar | 11.546 | 11.429 | 117 | 1,0% | 8,8% | 9,9% |
Apportal | 11.309 | 10.454 | 855 | 8,2% | 8,6% | 9,1% |
Sidevit B12 | 2.612 | 194 | 2.418 | 1249,5% | 2,0% | 0,2% |
Ultramag | 1.734 | 1.452 | 283 | 19,5% | 1,3% | 1,3% |
Altri | 3.079 | 2.907 | 172 | 5,9% | 2,3% | 2,5% |
Medical instruments | 6.816 | 5.922 | 894 | 15,1% | 5,2% | 5,1% |
Raw Materials | 2.799 | 2.071 | 728 | 35,1% | 2,1% | 1,8% |
Total | 131.709 | 115.498 | 16.211 | 14,0% | 100% | 100% |
*******
Please note that the revenue figures for financial year 2025 presented in this press release are preliminary and unaudited. The complete annual figures will be approved by the Board of Directors scheduled for March 17, 2026.
********
STATEMENT OF THE MANAGER RESPONSIBLE FOR PREPARING THE FINANCIAL REPORTSThe Manager responsible for preparing the company's financial reports, Francesco Sarti, declares, pursuant to paragraph 2 of Article 154 bis of the Consolidated Law on Finance, that the accounting information contained in this press release corresponds to the documentary results, accounting ledgers and records.
PharmaNutra S.p.A.Founded in 2003 in Pisa by Andrea and Roberto Lacorte, Pharmanutra is the holding company of an international Group engaged in the research, development, and commercialization of nutritional supplements, medical devices, and patented raw materials. A leader in iron-based supplements through its Sucrosomial® Technology (SiderAL® and Apportal®), and an emerging player in medical devices for mobility (Cetilar®), the Group internally manages the entire value chain and holds a solid portfolio of patents, brands, and clinical evidence. Pharmanutra operates in over 80 countries, with subsidiaries in the USA and Spain, and also includes Akern S.r.l. (bioimpedance analysis) and Athletica Cetilar S.r.l. (sports medicine).
PharmanutraGroup.com PharmaNutra.it
For further information:
PharmaNutra S.p.A. Press Office - Spriano Communication & Partners
Via Campodavela 1 - 56122 Pisa
Tel. +39 050 7846500
investorrelation@PharmaNutra.it
Internal Press Office press@calabughi.com
Via Santa Radegonda, 16 - 20121 Milan Tel. +39 02 83635708
Matteo Russo mrusso@sprianocommunication.com Cristina Tronconi ctronconi@sprianocommunication.com